CRISPR Replaces Immune Receptors in Personalized Cancer Cell Therapy

In a significant leap forward for personalized cancer treatments, scientists at PACT Pharma and the University of California, Los Angeles, have demonstrated the feasibility of isolating and cloning multiple TCRs that detect patients’ cancer cells, simultaneous knocking-out of endogenous TCRs and knocking-in of neoTCRs using precision genome editing, manufacturing edited T cells at clinical grade,…

Read the full article here

Related Articles